BIOEQUIVALENCE STUDY OF AZELNIDIPINE 16 MG TABLET TO EVALUATE PHARMACOKINETIC PROFILE OF SINGLE DOSE IN HEALTHY, ADULT, HUMAN VOLUNTEERS UNDER FASTING CONDITION
Keywords:Bioequivalence study, Pharmacokinetic, Azelnidipine, Human volunteers, Fasting condition
Objective: The present study's objective is to conduct a comparative bioavailability study with a special emphasis on the test product's bioequivalence using a standard reference product as a comparator.
Methods: Before initiating the bioequivalence study, the plasma sample analysis method was developed and validated by using LC-MS/MS method. The entire study was conducted as a single-dose crossover randomized bioequivalence study with open-label, two treatment, two-period, and two sequences on 24 healthy volunteers under fasting condition. With proper informed consent process the oral dose of the Reference product (R) or Test product (T) was administered on healthy volunteers at 0 h during each period of the study. After the drug's oral administration, a certain quantity of blood sample was collected, and the plasma sample was separated using a cold centrifuge. The plasma samples were analysed by using the validated LC-MS/MS method. The pharmacokinetic parameters, statistical data and ANOVA of the test and reference product were evaluated.
Results: The Cmax, Auc0-t, AUC0-∞ and tmax of the test product were found to be 6.29 ng/ml, 117.0 ng. h/ml, 161.67 ng. h/ml and 3.33 h. respectively. And the Cmax, Auc0-t, AUC0-∞ and tmax of reference product were found 6.59 ng/ml, 123.21 ng. h./ml, 172.20 ng. h/ml and 3.38 h respectively. Relative bioavailability was found 94.96%. The overall results show that the 90% confidence intervals (Log-Transformed and Untransformed) for Cmax, AUC0-t and AUC0-∞ for Azelnidipine were within the acceptable limit of 80%-125%.
Conclusion: The entire study's conclusion can be drawn as the test product was bioequivalence with the reference product's comparator.
Azelnidipine. CS 905, Calblock, RS 9054. Drugs R D 2003;4:122–5.
Kawabata K, Urasaki Y. Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2006;844:45–52.
Kawabata K, Samata N, Urasaki Y. Enantioselective determination of azelnidipine in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2007;852:389–97.
Tawaramoto K, Kaneto H, Hashiramoto M, Kawasaki F, Tatsumi F, Shimoda M, et al. Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in type 2 diabetes (BOAT2 study). Diabetol Metab Syndrome 2015;7:1-4.
Watanabe M, Hirano T, Okamoto S, Shiraishi S, Tomiguchi S, Uchino M. Azelnidipine, a long-acting calcium channel blocker, could control hypertension without decreasing cerebral blood flow in post-ischemic stroke patients. A 123 I-IMP SPECT follow-up study. Hypertens Res 2010;33:43.
Nada T, Nomura M, Koshiba K, Kawano T, Mikawa J, Ito S. Clinical study with azelnidipine in patients with essential hypertension. Arzneimittelforschung 2007;57:698-704.
Kiuchi S, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T, et al. Azelnidipine is a useful medication for the treatment of heart failure preserved ejection fraction. Clin Exp Hypertension 2017;39:350-4.
Catterall WA, Perez Reyes E, Snutch TP, Striessnig J. International union of pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 2005;57:411–25.
Nakano K, Egashira K, Tada H. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent associated neointimal formation in non-human primates. J Hypertens 2006;24:1881–9.
Nakamura T, Sugaya T, Kawagoe Y. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007;333:321–6.
Yamagishi T. Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine. Hypertens Res 2006;29:767–73.
Kario K, Sato Y, Shirayama M. Inhibitory effects of azelnidipine tablets on morning hypertension. Drugs R D 2013;13:63–73.
Sankyo Co. Calblock (azelnidipine) prescribing information Tokyo: Sankyo Co; 2003.
Zou JJ, Ji HJ, Zhou XH, Zhu YB, Fan HW, Xiao DW, et al. Determination of azelnidipine by LC–ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. Pharmazie 2008;63:568–70.
Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T. Antihypertensive effects of CS-905, a novel dihydropyridine Ca++channel blocker. Japan J Pharmacol 1989;51:57–64.
Wellington K, Scott LJ. Azelnidipine. Drugs 2003;63:2613–24.
‘Guideline on the investigation of bioequivalence’ (European Medicines Agency, London, CPMP/EWP/QWP/1401/98 Rev 1); 2010.
Halder D, Das S, Ghosh B, Biswas E, Roy S, Bose A, et al. An Lc-Ms/Ms based bioanalytical approach to resolve a pharmacokinetic investigation of acotiamide hydrochloride and its application to bioequivalence study. Int J Pharm Pharm Sci 2020;12:76-84.
Tijare LK, Rangari NT, Mahajan UN. A review on bioanalytical method development and validation. Asian J Pharm Clin Res 2016;9:6-10.
United States Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for orally Administered Drug Products; 2000.
The European Agency for the Evaluation of Medicinal Products EMA Committee for Proprietary Medicinal Products (CPMP) Note for guidance on the investigation of Bioavailability and Bioequivalence, London; 2001.
Ding L, Li L, Ma P. Determination of azelnidipine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal 2006;43:575-9.
How to Cite
Copyright (c) 2021 DIBYA DAS
This work is licensed under a Creative Commons Attribution 4.0 International License.